Asparaginase

Asparaginase
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Asparaginase is an enzyme used in the treatment of certain types of cancer, primarily acute lymphoblastic leukemia (ALL). It is an important component of chemotherapy regimens due to its ability to deplete the amino acid asparagine, which is essential for the growth and survival of certain cancer cells.

Mechanism of Action

Asparaginase works by catalyzing the hydrolysis of asparagine into aspartic acid and ammonia. Many cancer cells, particularly those in acute lymphoblastic leukemia, are unable to synthesize asparagine due to a lack of the enzyme asparagine synthetase. These cells rely on circulating asparagine for protein synthesis and survival. By depleting asparagine, asparaginase effectively starves the cancer cells, leading to cell death.

Clinical Use

Asparaginase is primarily used in the treatment of acute lymphoblastic leukemia (ALL), but it may also be used in other hematological malignancies such as non-Hodgkin lymphoma. It is often included in combination chemotherapy protocols, such as the Hyper-CVAD regimen.

Administration

Asparaginase can be administered intravenously or intramuscularly. The dosing schedule and route of administration depend on the specific treatment protocol and the formulation of asparaginase being used.

Side Effects

The use of asparaginase can lead to several side effects, some of which can be severe. Common side effects include:

• Hypersensitivity reactions, which can range from mild allergic reactions to severe anaphylaxis.
• Pancreatitis, which can be life-threatening and may require discontinuation of the drug.
• Coagulopathy, due to effects on the liver and protein synthesis.
• Hepatotoxicity, leading to elevated liver enzymes and potential liver damage.

Formulations

There are several formulations of asparaginase available, each with different pharmacokinetic properties and potential for allergic reactions:

• Native E. coli asparaginase: Derived from Escherichia coli, this formulation is associated with a higher incidence of hypersensitivity reactions.
• Pegaspargase: A pegylated form of E. coli asparaginase, which has a longer half-life and reduced immunogenicity.
• Erwinia asparaginase: Derived from Erwinia chrysanthemi, used in patients who develop hypersensitivity to E. coli-derived asparaginase.

Research and Development

Ongoing research is focused on improving the efficacy and safety of asparaginase. This includes the development of new formulations with reduced immunogenicity and enhanced pharmacokinetic profiles. Additionally, studies are exploring the use of asparaginase in other types of cancer and in combination with novel therapeutic agents.

Related Pages

• Acute lymphoblastic leukemia
• Chemotherapy
• Enzyme therapy
• Cancer treatment